Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2018 - 2026)

Takeda Pharmaceutical has reported Liabilities from Discontinued Operations for 8 years, with the latest figure at $14.9 million in Q2 2026.

• On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $14.9 million in Q2 2026; TTM through Jun 2026 was $14.9 million, a N/A change from a year earlier, with the FY2026 full-year figure at $5.2 million, changed N/A from the prior year.
• Liabilities from Discontinued Operations was $14.9 million for Q2 2026 at Takeda Pharmaceutical, up from $5.2 million in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was $14.9 million in Q2 2026, with the low at $1.1 million in Q1 2023.
• Average Liabilities from Discontinued Operations over 5 years is $7.1 million, with a median of $5.7 million recorded in 2022.
• The largest YoY upside for Liabilities from Discontinued Operations was 773.98% in 2024 against a maximum downside of 773.98% in 2024.
• Over 5 years, Liabilities from Discontinued Operations stood at $8.3 million in 2022, then slumped by 86.89% to $1.1 million in 2023, then surged by 745.6% to $9.2 million in 2024, then slumped by 44.66% to $5.1 million in 2025, then soared by 191.75% to $14.9 million in 2026.
• The last three Liabilities from Discontinued Operations figures came in at $14.9 million (Q2 2026), $5.2 million (Q1 2026), and $5.1 million (Q4 2025), per Business Quant data.